头孢曲松联合他唑巴坦在脆弱拟杆菌所致大鼠腹腔脓肿模型中的疗效

Efficacy of ceftriaxone plus tazobactam in a rat model of intraabdominal abscess due to Bacteroides fragilis.

作者信息

Pefanis A, Thauvin-Eliopoulos C, Eliopoulos G M, Moellering R C

机构信息

Department of Medicine, New England Deaconess Hospital, Boston, MA 02215.

出版信息

J Antimicrob Chemother. 1993 Aug;32(2):307-12. doi: 10.1093/jac/32.2.307.

DOI:10.1093/jac/32.2.307

PMID:8226433

Abstract

Using a rat model of intraperitoneal abscess due to Bacteroides fragilis, we evaluated therapy with the combination of ceftriaxone plus the beta-lactamase inhibitor tazobactam in comparison with ceftriaxone or cefotaxime alone. When treatment was begun five hours after bacterial challenge, final bacterial counts within abscesses at 3.5 days of treatment were as follows (mean +/- S.D., log10 cfu/g): ceftriaxone plus tazobactam, 4.15 +/- 1.25; cefotaxime, 4.77 +/- 1.80; ceftriaxone alone, 5.68 +/- 1.04; untreated controls, 9.14 +/- 1.13. In spite of pharmacokinetic differences between the two drugs, coadministration of tazobactam significantly enhanced activity of ceftriaxone in this model.

摘要

我们使用脆弱拟杆菌所致的大鼠腹腔脓肿模型，评估了头孢曲松联合β-内酰胺酶抑制剂他唑巴坦的治疗效果，并与单独使用头孢曲松或头孢噻肟进行比较。在细菌攻击后5小时开始治疗，治疗3.5天时脓肿内的最终细菌计数如下（平均值±标准差，log10 cfu/g）：头孢曲松加他唑巴坦，4.15±1.25；头孢噻肟，4.77±1.80；单独使用头孢曲松，5.68±1.04；未治疗的对照组，9.14±1.13。尽管两种药物在药代动力学上存在差异，但在该模型中，他唑巴坦与头孢曲松联合使用显著增强了头孢曲松的活性。